Management of Atrial Fibrillation in Patients with Hyperaldosteronism
Introduction to Treatment
- The American College of Cardiology recommends the use of mineralocorticoid receptor antagonists (MRAs) such as spironolactone or eplerenone, in addition to standard atrial fibrillation (AF) management, to decrease atrial fibrosis and reduce the susceptibility to AF in patients with hyperaldosteronism 1
Heart Rate Control in Atrial Fibrillation
- For patients with preserved ventricular function, beta-blockers or non-dihydropyridine calcium channel blockers (such as diltiazem or verapamil) are recommended for heart rate control in atrial fibrillation 2, 3, 4
- For patients with heart failure and reduced ejection fraction, beta-blockers are recommended as first-line treatment for heart rate control in atrial fibrillation 2, 4, 5
Rhythm Control
- The European Heart Journal suggests considering rhythm control strategies to improve quality of life in patients with atrial fibrillation 7, 1
- Options for electrical or pharmacological cardioversion should be considered based on patient characteristics 4, 1
- Catheter ablation may be considered as a second-line option if antiarrhythmic drugs fail 2, 1
Anticoagulation
- The European Heart Journal recommends anticoagulation based on the thromboembolic risk assessed using the CHA₂DS₂-VASc score 7, 4, 1
- Anticoagulation should be maintained regardless of whether the patient is in atrial fibrillation or sinus rhythm 1
- Direct oral anticoagulants (DOACs) or vitamin K antagonists are preferred over antiplatelet therapy 6, 5
Monitoring and Follow-up
- Regular evaluation of heart rate control, especially during exercise, is recommended 4, 1
- Regular echocardiographic evaluation to assess ventricular function and cardiac structural changes is recommended 7
- Reevaluation of the need for anticoagulation and adjustment of treatment according to clinical evolution is recommended 7, 1